Skip to main content
. 2021 Mar 17;11:640690. doi: 10.3389/fonc.2021.640690

Figure 2.

Figure 2

(A) Progression-Free Survival and (B) Overall Survival for Patients with Metastatic Breast Cancer in Phase I/Ib Clinical Trials Treated with IO Agents.